Stanford University
Showing 541-550 of 5,948 Results
-
Sinead Brennan-McMahon
Ph.D. Student in Classics, admitted Autumn 2019
BioSinead is an ABD PhD candidate in the Department of Classics and is expecting to complete her dissertation in 2024. Her research investigates ancient Roman sexual culture and where it shows up in the landscape. It focuses on displays of sexuality that do not match up to any social or political identities, including statues of Priapus, emperors portrayed as sexual aggressors and agricultural language adopted as sexual slang.
Sinead comes from Auckland, New Zealand, where she received her M.A. with First Class Honours. Her M.A. thesis examined the reception of Martial’s sexually obscene homosexual epigrams in school texts and commentaries. Using a comprehensive statistical analysis, she argued that Victorian editors of Martial’s Epigrams expurgated the text to remove references to material they found offensive and to curate a culturally appropriate view of the ancient world for their schoolboy readers.
Sinead is also interested in the Digital Humanities, Data Science and programming. As a CESTA DH Graduate Fellow, she is developing an ngram viewer tool for the Latin literary canon. -
Cort Breuer
Ph.D. Student in Immunology, admitted Autumn 2022
BioCort Breuer is currently an Immunology PhD student in the lab of Nathan Reticker-Flynn. Cort received his BS in Biological Engineering from Cornell University in 2022, where he studied lymphatic-cancer interactions and T cell mechanosensing in the lab of Esak Lee. Previously, he worked with James Moon at Massachusetts General Hospital to develop in vivo gene therapies for the immune system and with Michelle Krogsgaard at NYU Perlmutter Cancer Center to investigate structural biology of TCR signaling. Cort’s current work focuses on mechanisms of tumor-immune tolerance and decoding the antigen specificity of T cell receptors. Drawing on his engineering background, he designs new molecular tools to record how immune cells communicate and constructs therapeutics to target impaired immune responses.
